Please login to the form below
naltrexone
This page shows the latest naltrexone news and features for those working in and with pharma, biotech and healthcare.
FDA panel backs Pfizer and Teva abuse-resistant painkillers
The panel also voted by nine votes to six in favour of approving Pfizer's Troxyca ER (oxycodone/naltrexone) for the sane indication. ... In the case of Troxyca ER, the inclusion of opioid blocker naltrexone is designed to achieve the same end result.
Latest news
-
Takeda files block on generic diet pill launch
The lawsuit alleges that the generic drugmaker Actavis has infringed patents on Orexigen and Takeda's new weight-loss treatment Contrave (naltrexone and bupropion).
-
Saxenda debuts in US with $1,000-a-month price tag
s Contrave (bupropion/naltrexone), Arena/Eisai's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), although for patients the monthly cost will fall depending on their insurance cover.
-
Positive data in Saxenda diabetes prevention study
the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion).
-
CHMP thumbs up for Novo's obesity drug Saxenda
new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world
-
Orexigen’s obesity pill Mysimba set for European approval
The drug is a combination of the antidepressant bupropion and Orexigen's formulation of naltrexone, a drug designed to prevent drug dependence. ... The CHMP has recommended a marketing authorisation for Mysimba (naltrexone/bupropion) for weight
More from news
Approximately 5 fully matching, plus 24 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Great salary and bebefits
-
Senior Programme Executive
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Project Manager, Medical Communications, London
-
Excellent Salary
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Account Manager – Med Comms – London
-
Salary TBC
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Senior Account Director, Healthcare Brand Communications, London
-
Excellent Package
- Project Manager, Medical Communications, Oxford
-
Excellent Salary
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Medical Writer, e-learning/ training, London
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- BenevolentAI raises $115m to fund drug development
- Shire rebuffs Takeda bids, as Allergan bows out
- Abeona Therapeutics names CEO
- Zelluna Immunotherapy appoints chief technology officer
- Spirit Health Group offers new market access consultancy service
- Why heading online for scientific meetings can yield greater HCP engagement
PMHub
SpotMe
SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...
Latest intelligence
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Quick links
Infographics
